-
Mashup Score: 3
Gentry King, MD, discusses an ongoing feasibility study on multiomic platform‑based testing in patients with localized and resectable biliary tract cancers.
Source: Oncology Leanring NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Certain treatment options when added to androgen-deprivation therapy (ADT) have improved overall survival (OS) among those with metastatic castration-sensitive prostate cancer (mCSPC).
Source: Oncology Leanring NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
To learn more about this discovery, visit: https://t.co/vX8u2bUXHP #ProstateCancer #ADTTherapy #MedTwitter https://t.co/TBB43YPBUi
-
-
Mashup Score: 0
Mattea Reinisch, MD, highlights the final efficacy and safety results of the phase 3b, multi-center, open-label Ribecca trial for women with ER+, HER2- locally advanced or metastatic breast cancer, presented as a poster at the virtual 2020 SABCS meeting.
Source: Oncology Leanring NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Mattea Reinisch, MD, highlights the final efficacy and safety results of the Ribecca trial for #women with ER+, HER2- locally advanced or metastatic #breastcancer, presented as a poster at the virtual @SABCSSanAntonio meeting. Watch Here: https://t.co/snmfbm9CTH https://t.co/G38Qyc2Bp8
-
-
Mashup Score: 0Surgery Plus Systemic Therapy Improves Outcomes in Stage IV GIST - 3 year(s) ago
A study evaluating treatment methods of stage IV GIST found surgery in combination with systemic therapy demonstrates the best outcomes for patients.
Source: Oncology Leanring NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A #study evaluating #treatmentmethods of stage IV #GIST found surgery in combination with systemic therapy demonstrates the best outcomes for #patients. Learn More: https://t.co/CNLOHdpDCQ https://t.co/0vb8QKVZ3j
-
-
Mashup Score: 0Julie Kanter, MD, Talks QoL Outcomes After Lentiglobin Gene Therapy for Sickle Cell Disease - 3 year(s) ago
Dr Kanter discusses lentiglobin gene therapy for sickle cell disease, QoL data from ASH 2020, and how measuring outcomes for these patients can be improved.
Source: Oncology Leanring NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr Kanter, @UofAlabama, provides an overview on lentiglobin #genetherapy for sickle cell disease, quality of life data from the virtual @ASH_hematology Annual Meeting, and how measuring outcomes for these #patients can be further #improved. Watch Here: https://t.co/De6U7GK44m https://t.co/C5gJO8CPsB
-
-
Mashup Score: 0FDA Approves Cemiplimab-Rwlc for laBCC, mBCC - 3 year(s) ago
The FDA has approved cemiplimab-rwlc, a PD-1 blocking antibody, for the treatment of patients with locally advanced basal cell carcinoma (laBCC) and has metastatic BCC (mBCC).
Source: Oncology Leanring NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The @US_FDA has #approved cemiplimab-rwlc, a PD-1 blocking antibody, for the #treatment of #patients with locally advanced basal cell #carcinoma (laBCC) and has metastatic BCC (mBCC). Learn More: https://t.co/ZDcD5OmDPA @FDA_Drug_Info #MedTwitter #MedResearch #BreakingNews https://t.co/t4dLDrQOpE
-
-
Mashup Score: 1
In a study of adults transplanted for high-risk AML or MDS, an intensified RIC regimen did not improve outcomes, regardless of pretransplant MRD status.
Source: Oncology Leanring NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
To learn more about this study, visit: https://t.co/Vp7BMKE0kJ #MedTwitter #AML #CancerResearch #Oncology https://t.co/1WZ62mm4Tf
-
-
Mashup Score: 0
Lanreotide combined with pembrolizumab led to stable disease with acceptable safety in nearly 40% of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs), according to results published at the virtual 2021 ASCO GI Cancers Symposium.
Source: Oncology Leanring NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Lanreotide combined with pembrolizumab led to stable disease with acceptable safety in nearly 40% of #patients with GEPNETs, according to results published at the virtual 2021 @ASCO GI Cancers Symposium. Learn More: https://t.co/yqo3YpTq3c #ASCOGI #MedTwitter #Oncology https://t.co/p6y1ZdqYNC
-
-
Mashup Score: 1
Study findings suggest that eprenetapopt plus azacitidine is well-tolerated and leads to high rates of response and remission in patients with TP53-mutant MDS and oligoblastic AML.
Source: Oncology Leanring NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Research suggests eprenetapopt plus azacitidine is well-tolerated and leads to high rates of response and #remission in #patients with TP53-mutant MDS and oligoblastic AML. Learn More: https://t.co/BPTptt04gW #MedTwitter #LeukemiaResearch https://t.co/smS6kAVkHb
-
-
Mashup Score: 0Alexey Danilov, MD, PhD, Discusses the Use of Acalabrutinib for the Treatment of CLL, SLL, and MCL - 3 year(s) ago
In this video, Dr Danilov discusses the use of acalabrutinib as a treatment option for patients with CLL, SLL, and MCL.
Source: Oncology Leanring NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this video, Dr Danilov, @OHSUNews, discusses the use of #acalabrutinib, (@CalquenceHCP) as a treatment option for #patients with CLL, SLL, and MCL. Watch Here: https://t.co/UULj3g798S #MedEd #MedTwitter #Healthcare https://t.co/0FHgk0h1V1
-
Dr King, @SeattleCCA, @fredhutch, discusses an on-going feasibility study on multiomic platform‑based testing in #patients with localized, resectable #biliarycancer. Watch Here: https://t.co/W3ULZ0PWqM https://t.co/pWrqq2iUEr